merck

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Big Pharma Looks Beyond Drugs to Smartphone Apps

Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.

Two Reasons for Clinical Data Shares to Soar Again

From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver. As the number of people with diabetes and prediabetes explodes, drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

Which Sector Lost the Most Jobs in 2010? Pharma

If you don't count the U.S. government and nonprofits, the pharmaceutical industry had the most job cuts last year. Mergers, acquisitions and major restructurings made pharma a much smaller and leaner sector -- will those changes now play in its favor?

What a Wild Year It Was
for Health Care

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.

Merck KGaA Is Latest Pharma to Settle Justice Department Claims

German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.

Stocks Close Higher for the Week, Once Again

The last full trading week of 2010 has closed and stocks were modestly mixed trading on light volume. While pharmaceutical giants Pfizer and Merck put a damper on the Dow, robust earnings from Oracle and Research In Motion helped lift tech stocks.

Johnson & Johnson Recalls Mylanta Over Labeling

If you get the feeling Johnson & Johnson is recalling products every day, you wouldn't be that far from the truth. Now it's dragging Merck with it as the two announced a recall of 12 over-the-counter Mylanta heartburn medicine liquid products as well as Alternagel liquid antacid to update product labeling.

Richard Branson Latest Mogul to Launch an iPad Magazine

Richard Branson is pushing beyond the revenue curve with a new iPad magazine he plans to show to the public next week. The British mogul bills it as a as a paperless "revolutionary multimedia" publication. First word of the project -- dubbed, simply, Project -- leaked out in July, but the effort has been kept under tight wraps.

Pharma News Briefs: Human Genome, Merck, Novartis

Here's a roundup of some of Wednesday's major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck's experimental heart drug appears to work well without side effects; and Novartis announced its plans for long-term growth.

How to Approve 'Biosimilar' Drugs? The FDA Has to Figure That Out

Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years for the FDA to create an approval process.

Growing Interest
in Achillion's Hepatitis Drugs

At a liver disease conference in Boston, one of the highlights is expected to be reports from Achillion about its novel hepatitis C treatments, especially ACH-1625. The buzz is growing stronger that the little biotech is attracting the attention of some players in Big Pharma.

Merck Earnings Hurt by Schering Acquisition Charge

Pharmaceutical giant Merck announced mixed third-quarter results Friday, but lifted the lower end of its 2010 earnings guidance. Net income for the third quarter was $342 million, or 11 cents per share, as earnings were impacted by a large charge.

A New Antidepressant Maker Has Lots of Folks Excited

Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK'd, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are said to looking to buy the startup.

Pharmas Probed Over Foreign Bribery Allegations

Federal investigators are looking into allegations that major drug companies, including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline, paid bribes overseas to boost sales and accelerate approvals.

Hedge Your Risk With Mixed-Asset Mutual Funds

With stocks underperforming so far in 2010, and Treasury bond yields low, too, Standard & Poor's Equity Research suggests investing in mixed-asset mutual funds, which hold a combination of stocks and bonds to capture the strengths of both asset classes with less volatility.

CEOs Who Laid Off More Got Paid 42% More Money

CEOs who cut the most jobs during the recession earned an average of 42% more than their S&P 500 peers, according to a study by the Institute for Policy Studies. Top execs at the 50 firms that laid off the most workers since the economic crisis began averaged nearly $12 million in 2009.

The 25 Companies That Cut 700,000 Jobs

Since the recession began, more than 8 million Americans have lost their jobs. But perhaps even more surprising is the small number of companies that are responsible for laying off such a large percentage of today's unemployed workers.

Dow, S&P 500 Post Best Monthly Gains in a Year

Some robust blue-chip earnings and an improvement in consumer sentiment helped stocks shrug off a disappointing reading on economic growth to end mixed Friday -- but the market still enjoyed its biggest monthly gain in a year.